key: cord-0837939-tt7qx7u7 authors: Wang, Yang; Lu, Xiaofan; Li, Yongsheng; Chen, Hui; Chen, Taige; Su, Nan; Huang, Fang; Zhou, Jing; Zhang, Bing; Yan, Fangrong; Wang, Jun title: Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19 date: 2020-06-01 journal: Am J Respir Crit Care Med DOI: 10.1164/rccm.202003-0736le sha: 1948a4188065b249351ff8b33855193a9f67e162 doc_id: 837939 cord_uid: tt7qx7u7 nan defined per the International Society of Thrombosis and Haemostasis, and acute kidney injury was diagnosed according to the Kidney Disease Improving Global Outcomes clinical practice guidelines (6) . Myocardial damage was diagnosed according to the serum levels of cardiac biomarkers or new abnormalities in electrocardiography and echocardiography. Liver injury was diagnosed according to elevation of bilirubin and aminotransferase. Rhabdomyolysis was diagnosed on the basis of the serum level of creatine kinase and myoglobin. Survival endpoint was 28-day mortality after admission to the intensive care ward. The Ethics Commission of Tongji hospital approved this study, with a waiver of informed consent. Continuous variables are presented as median (interquartile range [IQR] ), whereas categorical variables were expressed as frequencies (%). Statistical analyses were conducted with R3.6.2 (https://www.r-project.org/) using a Fisher's exact test for categorical data and Mann-Whitney test for continuous data; Kaplan-Meier estimator and Cox regression were used for survival analysis. Correlations were measured by Spearman's method (r). For unadjusted comparisons, a two-sided P less than 0.05 was considered statistically significant. Characteristics and treatment. Of the 344 intensive care patients (Table 1) , nonsurvivors are generally older than survivors, with a higher proportion aged over 60 years, and every 10-year increase in age was associated with a 58% additional risk (hazard ratio [HR], 1.58; 95% confidence interval [CI], 1.38-1.81; P , 0.001). Dyspnea was more common in nonsurvivors, accompanied by a significantly higher respiratory rate and lower Sp O 2 /FI O 2 (S/F) ratio; S/F was negatively correlated (r = 20.68) with the incidence of ARDS, and every 10-U increase in S/F correlated with a 10% decrease in fatality (HR, 0.90; 95% CI, 0.88-0.92; P , 0.001). A total of 128 out of 145 (88.3%) patients who developed ARDS died at or before 28 days. Nonsurvivors were more likely to bear original comorbidities (all P < 0.05). Lymphocytopenia occurred in 237 (69.5%) subjects and was predominant in nonsurvivors (91.6% vs. 55.7%; P , 0.001); higher lymphocyte count was significantly associated with decreasing mortality (HR, 0.1; 95% CI, 0.06-0.18; P , 0.001). A total of 283 (82.3%) patients received antiviral agents, and 266 (77.3%) received antibacterial agents. Other supportive treatments, including g globulin (156 [45.3%]), muscle relaxant (38 [11.0%]), and glucocorticoids (225 [65.4%]), were given to the patients. Two (0.6%) patients were treated with extracorporeal membrane oxygenation, and nine (2.6%) with continuous renal replacement therapy. Ventilatory support. A total of 35 (10.2%) patients were treated with HFNC, of whom 23 (65.7%) also received invasive ventilation. Of the 12 patients who received HFNC only, 7 (58.3%) died at or before 28 days. A total of 134 (40.6%) patients were treated with mechanical ventilation (either noninvasive or invasive), of whom 34 received treatment of noninvasive ventilation only, and 27 (79.4%) died at or before 28 days, whereas invasive ventilation was given to 100 patients, with 97 (97%) deaths at or before 28 days. Median duration from admission to invasive ventilation was 5 (IQR, 1-8) days, and median duration of invasive ventilation was 4 (IQR, [3] [4] [5] [6] [7] [8] Clinical course and outcomes. A total of 133 (38.7%) patients died at or before 28 days, with a median survival of 25 days (Figure 1 ). For nonsurvivors, median duration from admission to death was 10 (IQR, 6-15) days. Of the 211 survivors, 185 (87.7%) were discharged. Median duration from onset of symptoms to laboratory confirmation of infection by RT-PCR was 8 (IQR, [5] [6] [7] [8] [9] [10] [11] days. In survivors, median duration from positive to negative RT-PCR result was 12 (IQR, [9] [10] [11] [12] [13] [14] [15] days, whereas, in nonsurvivors, median duration from infection confirmation to death was 15 (IQR, 10-19) days ( Figure 1 ). This report, to our knowledge, is the largest case series of patients with COVID-19 in intensive care, with informative laboratory characteristics, detailed clinical course, and outcome. In our cohort, nonsurvivors were older than survivors, which is consistent with an earlier study (7) . We did not observe survival differences in regard to sex, but this is inconsistent with the results of a previous study (8) . Compared with survivors, nonsurvivors presented more commonly with dyspnea and a higher respiratory rate, indicating that more attention should be paid to changes in vital (9) . In addition, S/F may be a useful and noninvasive predictive marker, which was defined by the Kigali modification of the Berlin definition and had good correlation with the diagnosis of ARDS (10). Given a large patient flow during epidemic conditions, this indicator could be flexibly used for screening and monitoring. Lymphocytopenia occurred in almost 70% and was predominant in nonsurvivors, which contradicts a previous study with a relatively small sample size (8) . Lymphocytopenia is a prominent feature of critically ill patients with SARS (11) and Middle East respiratory syndrome, which is the result of apoptosis of lymphocytes (12) ; thus, lymphocyte depletion could be harmful, and lymphocyte count might serve as another prognostic factor for SARS-coronavirus 2 (SARS-CoV-2). In addition, we observed a higher level of hs-CRP (high-sensitivity C-reactive protein), along with other inflammatory markers, which is consistent with relevant reports of SARS and Middle East respiratory syndrome (13) . Unexpectedly, however, nonsurvivors showed a higher level of IL-2R. Highly expressed IL-2R initiates autoreactive cytotoxic CD8 1 T-cell-mediated autoimmunity. Meanwhile, IL-2 stimulates the proliferation of natural killer cells that highly express IL-2R, promoting the release of cytokines, further inducing the lethal "cytokine storm" (14) . We also observed that factors, such as red blood cell distribution width, lactate dehydrogenase, and coagulation index, were upregulated in nonsurvivors, which was probably due to their active participation in inflammatory response. It has been reported that chest computed tomography imaging can be more sensitive diagnostically compared with RT-PCR (15), and we reasoned that computed tomography might even show guiding significance in the critical stage of COVID-19. The high mortality rate of patients who received mechanical ventilation may have been due, in part, to the centralized admission of a large number of intensive care patients in February and the fact that patients were sometimes transferred late to the hospital. These conditions made us question the effectiveness of noninvasive ventilation treatment or HFNC in the first line, and whether the early use of invasive ventilation would improve prognosis. Both questions may be worth further study in a larger cohort. In summary, in this single-center case series study, older patients with comorbidities are at dramatically increased risk of mortality. Real-time monitoring of S/F and regular measurements of lymphocyte count and inflammatory markers may be essential to disease management. n To the Editor: The dramatic improvement in prognosis for individuals with cystic fibrosis (CF) must not be overlooked in deliberations about the use of intensive care during the coronavirus disease (COVID-19) pandemic. Thanks to advances in treatment options and improvements in care, the median predicted survival for people with CF in the United States is approaching 50 years of age and steadily climbing (1) . With the recently approved combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta), which addresses the basic defect in CF, many people with CF are experiencing transformational improvements in quality of life and lung function that will undoubtedly further increase survival. For patients with advanced CF lung disease, the outlook has also dramatically improved. Before the U.S. Food and Drug Administration approved Trikafta, the median survival for patients with CF and FEV 1 , 30% predicted was shown to be .6.5 years (2) . Recent studies reveal improving critical care outcomes, with unanticipated survival and functional recovery from respiratory failure precipitated by influenza and other acute infections. These data prompted the developers of the 2020 Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced CF to recommend that these individuals should be considered eligible for intensive care (3). As states and hospitals turn to emergency triage plans to ensure that scarce medical resources are allocated wisely, we are concerned that some plans use the mere presence of existing health conditions, including CF, as a determining factor in these decisions. This approach fails to recognize that CF has a wide range of disease manifestations. Just as importantly, putting CF in the same category as other chronic lung diseases fails to account for the fact that individuals with CF typically are decades younger and more functional than those with more common chronic lung diseases. Although it is important to give frontline healthcare workers guidance during this crisis, considering all chronic lung diseases as similar, both as a risk factor for higher mortality from COVID-19 pneumonia and as a rationale for denying life-saving intensive care to people with CF, is too simplistic. Alarmingly, several states have created regional triage plans that reflect an outdated understanding of CF and run the risk of denying care without taking current clinical realities into account. For example, Tennessee includes the presence of CF with FEV 1 , 30% as a reason for denying hospital admission (4) . Although risk stratification is important when allocating resources, the blanket exclusion of individuals with CF and FEV 1 , 30% predicted is based on an inaccurate understanding of the current survival outcomes for patients with CF and does not factor in the short-and long-term impacts of disease-modifying CF therapy. The University of Pittsburgh has proposed an algorithm that looks beyond the presence of an underlying condition with the application of a multiprinciple allocation framework to aid providers in these difficult times (5) . This algorithm uses a life expectancy of ,5 years, before COVID-19 infection, as an indicator of lower priority for critical care or ventilator use. Individuals with CF and FEV 1 , 30% predicted have a predicted median survival of .5 years, and that rate predates the widespread availability of the transformational therapy Trikafta. Accordingly, individuals with advanced CF lung disease should not have a lower priority for intensive care. China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China Diagnosis and management of COVID-19 disease National Health Commission of the People's Republic of China. Chinese management guideline for COVID-19 (version 6.0) The Third International Consensus definitions for sepsis and septic shock (Sepsis-3) ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study ACE2: from vasopeptidase to SARS virus receptor Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the Berlin definition Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease Interleukin 2: from immunostimulation to immunoregulation and back again Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases